Pfizer's Camptosar To Serve As Example Of Pharmacogenetic Toxicity Risk At Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Irinotecan will be used as an example of pharmacogenetic toxicity risk at Clinical Pharmacology Subcommittee meeting Nov. 3-4. Pfizer is discussing label changes with FDA regarding Camptosar use in patients with certain genotypes. Subcommittee will also address the transition of biomarkers to surrogate endpoints.